Skip to content

Sridhar Vasudevan

3 papers in the library · 12 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.

British Journal of Pharmacology June 22, 2025 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 9 citations

Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5-HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5-HT2A receptor ligand bias or signalling efficacy. Here, we investigated 5-HT2A receptor signalling properties of...

Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy.

Journal of Sleep Research May 10, 2025 Brooke A Prakash, Ishani Shah, Guohao Ni et al. 2 citations

Throughout history, the development of new sleep medicines has been driven by progress in our understanding of the mechanisms underlying sleep. Ancient civilisations used their understanding of the sedative nature of natural herbs and compounds to induce sleep. The discovery of barbiturates and bromides heralded a new era of synthetic sleep medicine in the 19th century. This was followed by the...

Increased 5-HT 2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics

bioRxiv (Cold Spring Harbor Laboratory) June 16, 2024 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 1 citation preprint

ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric disorders. While all serotonergic psychedelics have 5-HT 2A receptor activity, the explanation for why some 5-HT 2A receptor agonists are not psychedelic is unknown. To address this question, we investigated the 5-HT 2A receptor signalling bias and...